1-3 of 3
Konrad Van Der Zwet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluating the Clinical Relevance of Thrombin Generation Potential during Emicizumab Therapy

Konrad Van Der Zwet, Mark Roest, Dana Huskens, Eduard J. Van Beers, Kathelijn Fischer, Lize Fie Ditteke Van Vulpen, Roger EG Schutgens, Rolf T. Urbanus
Journal: Blood
Blood (2024) 144 (Supplement 1): 3960.
https://doi.org/10.1182/blood-2024-204587
Published: 2024
Journal Articles

Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

Konrad Van Der Zwet, Marjon H. Cnossen, Floor CJI Moenen, Saskia EM Schols, Paula F Ypma, Paul L. den Exter, Louise Hooimeijer, Michiel Coppens, Ron A.A. Mathôt, Anouk A.M.T. Donners, Alexander Janssen, Ilmar Kruis, Eduard J. Van Beers, Corien L. Eckhardt, Rolf T. Urbanus, Lize Fie Ditteke Van Vulpen, Roger EG Schutgens, Kathelijn Fischer
Journal: Blood
Blood (2024) 144 (Supplement 1): 127.
https://doi.org/10.1182/blood-2024-193995
Published: 2024
Journal Articles

The Emicizumab Switch: Real-World Data of 251 Pediatric Patients from the Pednet Registry

Konrad Van Der Zwet, Marloes de Kovel, Jayashree Motwani, Christel Van Geet, Beatrice Nolan, Heidi Glosli, Gili Kenet, Kathelijn Fischer
Journal: Blood
Blood (2022) 140 (Supplement 1): 8442–8443.
https://doi.org/10.1182/blood-2022-162181
Published: 2022